News – Page 4 – FSD Pharma

Blog

FSD Pharma welcomes legislation to allow private retail of cannabis in Ontario

TORONTO, Sept. 27, 2018 /CNW/ – FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”), is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, today congratulates the Ontario government for introducing legislation that would open up recreational cannabis retail to the private sector. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts, research and development.

“We are excited that the Ontario government has decided to open up the retail market for recreational cannabis to the private sector and recognize this as a great opportunity for the growth of our sector,” said Thomas Fairfull, President and CEO of FSD Pharma. Continue Reading

FSD Pharma Added to Leading Cannabis ETF with Significant 1.9% Weighting

TORONTO, September 27, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce that Horizons ETFs Management (Canada) Inc. (“Horizons ETFs”) has added the Company to the Horizons Marijuana Life Sciences Index ETF (“HMMJ:TSX”) as part of the quarterly rebalance of the constituent holdings of HMMJ. The Company stock has a 1.9% weighting in HMMJ. According to Horizons ETFs, “As at September 5, 2018, HMMJ had reached over CAD $1 billion in assets under management – a rare achievement for the Canadian ETF marketplace”.[1]

“We are thrilled to be included in HMMJ, which is the largest ETF offering direct exposure for investors to North American life sciences companies that have significant business activities in the marijuana industry. FSD Pharma expects to continue to deliver on its current business strategy and expansion plan in preparation for adult-use legalization on October 17, 2018,” said Anthony Durkacz, Director of FSD Pharma.

[1] http://www.newswire.ca/en/releases/archive/September2018/26/c3045.html

About FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9)

FSD Pharma through its wholly-owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) having received its cultivation license on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FV Pharma management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.

Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

FSD Pharma Receives First Delivery of Canntab Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets Per Day

TORONTO, Sept. 25, 2018 /CNW/ – FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the Company has received its first delivery of manufacturing equipment at its Cobourg plant from Canntab Therapeutics Limited (CSE:PILL) (“Canntab”), a leader in the rapidly growing cannabis pill market. The manufacturing equipment consists of a fully GMP High output Tablet press capable of pressing more than 1,500,000 tablets per day, as well as blending machinery, large scale process and drying equipment and packaging equipment.

Mr. Jeffrey Renwick, Chief Executive Officer of Canntab, stated, “With this first delivery of manufacturing equipment at the Cobourg plant, we can begin the process of setting up our manufacturing space in collaboration with FSD Pharma. We expect manufacturing of our suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets to begin in earnest.”

Zeeshan Saeed, EVP and Director of FSD Pharma, added, “We are thrilled that Canntab is moving so quickly to set up its manufacturing facility at our Company. We too are moving quickly to build out our own 220,000 square feet of additional manufacturing capacity in Cobourg in collaboration with Auxly. This is truly an exciting time at FSD Pharma.”

FSD Pharma and Canntab previously announced the signing of a definitive collaboration and profit sharing agreement (the “Agreement”) effective September 17, 2018. Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the “License”), and will provide Canntab with space at its facility (the “FSD Facility”), which is located just one hour east of Toronto in Cobourg, Ontario (the “Transaction”).

FSD Pharma will provide Canntab with up to 10,000 square feet of space at the FSD Facility (the “Canntab Premises”). Canntab will build and install, at its expense, its own manufacturing facility within the larger FSD Facility that will operate in accordance with Good Manufacturing Practices, at which it will produce a suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets, and other types of cannabis-based products, including sleep aids and pain relievers (the “Canntab Products”).

FSD Pharma and Canntab see tremendous opportunity in offering pharmaceutical quality cannabis based tablets, as many doctors are adverse to prescribing smoked cannabis as a solution to patients’ health concerns. The Canntab Premises are intended to be used to supply Canadian and International markets such as Australia and Germany, which legally allow cannabis. FSD Pharma will work with Canntab to prepare the necessary items to submit an application from Canntab to Health Canada to obtain the License, which will be attached to the Canntab Premises. In particular, FSD Pharma will assist with the following aspects of the application:

a) drafting, or coordinating the drafting of, all application materials;
b) sourcing all necessary third-party consultants required to prepare the application; and
c) communicating with Health Canada throughout the application process.

In consideration of FSD Pharma’s services, Canntab will grant FSD Pharma certain royalty and profit sharing rights in connection with the sale of the Canntab Products. Canntab will provide FSD Pharma with 50% of the profits that Canntab receives on any retail sales of Canntab Products through channels that are established by FSD Pharma and FSD Pharma will be entitled to retain 50% of the profits on FSD Pharma’s sales of the Canntab Products. In addition, Canntab will pay FSD Pharma a royalty of 3.5% of Canntab’s sale price for all Canntab Products that are manufactured and sold from the Canntab Premises. Canntab may also purchase the oil that it requires for the Canntab Products from FSD Pharma.

About FSD Pharma

FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FSD Pharma’s management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development. Please visit www.fsdpharma.com for more information.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!

Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.

FSD Pharma and Scicann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University

Toronto – September 23, 2018/CNW/ – FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce the launch of a comprehensive sponsored research program in Tel Aviv University together with its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”), focused on the cardiovascular disease field. The new research program is aimed at the development of novel and proprietary cannabinoid-based treatments for the prevention and treatment of atherosclerosis, the underlying factor for most cases of stroke and cardiac stenosis events in the western world.

Dr. Zohar Koren, Co-founder and CEO of SciCann stated, “The prevalence of Coronary Artery Disease (CAD) among adults in North America is estimated at 8% of the population and considered to be the number one killer disease in the western world. There is a high unmet need for novel, safe and natural therapies that will ameliorate the damage caused by atherosclerotic plaques to the arteries and cardiovascular system and we believe that smart and targeted modulation of the endocannabinoid system may offer a new approach to treat this devastating progressive disease. We are highly excited to launch this new research program in Tel Aviv University and use the sophisticated and advanced labs that it offers for the execution of this program.” Continue Reading

FSD Pharma inc. announces $7.5 Million Dollar at $1 per share investment as part of existing strategic alliance with Auxly Cannabis Group Inc.

TORONTO, September 20, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) is pleased to announce that pursuant to the approved construction and development budget announced on July 3, 2018 (Link), Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly”) has made an equity investment into the Company at $1.00 per Class B Subordinate Voting Share for total proceeds of $7.5 million. No fees were paid to brokers in connection with the transaction.

All of the securities issued in connection with the Offering are subject to a hold period expiring on January 20, 2019.

Proceeds of the financing will be deployed toward construction of the 220,000 square foot cultivation footprint that FSD and Auxly are jointly developing pursuant to their strategic alliance and streaming agreement previously announced on March 5, 2018 (the “Joint Cultivation Footprint”) (Link). The buildout of the Joint Cultivation Footprint is currently underway in Cobourg, Ontario and will include dedicated space for large scale extraction capabilities. Continue Reading

FSD Pharma Announces Upgraded Listing to OTCQB Venture Market

TORONTO, September 19, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (FRA: 0K9) announced today that its subordinate voting shares have been upgraded to a listing on the OTCQB (“OTCQB”) Venture Market, trading under the ticker symbol “FSDDF.” The Company’s subordinate voting shares continue to be listed on the Canadian Stock Exchange (“CSE”) under the ticker symbol “HUGE” and on the Frankfurt Stock Exchange (“FRA”) under the ticker symbol “0K9.”

“We are excited to be upgraded to a listing on the OTCQB Venture Market for early stage and developing U.S. and international companies. This new listing allows U.S. investors the opportunity to further share in the Company’s continued expansion and growth internationally,” said Zeeshan Saeed, EVP and Director of FSD Pharma. “U.S. investors can obtain Real-Time quotes and market information for the Company at www.otcmarkets.com and access the most current company news and developments.”

About FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9)

FSD Pharma through its wholly-owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) having received its cultivation license on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FV Pharma management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.

Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

FSD Pharma Signs Collaboration and Profit Sharing Agreement With Canntab for Production and Market of Oral Dose Delivery Platforms

Toronto, September 18, 2018 (CNW) – FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the “Agreement”) with Canntab Therapeutics Limited (CSE:PILL) (“Canntab”), a leader in the rapidly growing cannabis pill market, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the “License”), and will provide Canntab with space at its facility (the “FSD Facility”), which is located just one hour east of Toronto in Cobourg, Ontario (the “Transaction”).

FSD Pharma will provide Canntab with up to 10,000 square feet of space at the FSD Facility (the “Canntab Premises”). Canntab will build and install, at its expense, its own manufacturing facility within the larger FSD Facility that will operate in accordance with Good Manufacturing Practices, at which it will produce a suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets, and other types of cannabis-based products, including sleep aids and pain relievers (the “Canntab Products”). Continue Reading

FSD Pharma joins Snipp’s Cannabis Marketing Resource Center

TORONTO, Sept. 17, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) today announced that it has joined the Cannabis Marketing Resource Center (“CMRC”) provided by Snipp Interactive Inc. (“Snipp”) (OTCQB: SNIPF; TSX-V: SPN), a global provider of digital marketing promotions, rebates and loyalty solutions. FSD has now joined some of the largest licensed producers in Canada that currently use the CMRC and the technology solutions provided by Snipp.

“As the Cannabis industry begins to scale, it becomes important to invest in best of breed software and technology solutions to enable companies like ours to sell our products across the ecosystem from seed to sale. We look forward to working with Snipp, a leader in supplier/customer activation and retention programs, to develop such programs and learn from their expertise in similar regulated industries like Pharmaceuticals, Alcohol & Tobacco”, said Anthony Durkacz, Director of FSD Pharma.

“We are very excited by the continued interest received in our CMRC. FSD is a great example of a forward looking company that intends to run a vertically integrated business that is already thinking through the finer points of their future business and operating model. With the successes they have already had, I am sure that our relationship is only just beginning today and will evolve along with their business needs,” said Atul Sabharwal, CEO of Snipp.

The goal of the CMRC is to help Cannabis companies hit the ground running by leveraging SNIPP’s deep expertise and the flexible technology platforms it has engineered for highly-regulated industries, which have unique requirements compared to other consumer-oriented segments. The CMRC resource center is designed to help cannabis-related companies launch sophisticated solutions that are also legally-compliant, a very important aspect for all firms in the cannabis space. Continue Reading

FSD Pharma to Expand Into Jamaican Market and Introduce FSD Jamaica

TORONTO, September 13, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that it intends to launch a strategic partnership into the Jamaican cannabis market as part of its plan to expand internationally. FSD has signed a Letter of Intent (“LOI”) effective September 10, 2018 with JJAMACANN Inc. (“JJAMACANN”) to form a joint venture operating as FSD Jamaica (“FSD Jamaica”). FSD Jamaica expects to partner locally with Nature’s Purest Limited (“NPL”), a Jamaican corporation with a cultivation license and existing operations in Jamaica.

“We are excited to be working with a world-class and knowledgeable team of local experts and entrepreneurs with extensive cannabis cultivation experience. Jamaica has historically produced some of the best cannabis over the past 50 years. FSD Jamaica intends to take advantage of the ideal climate and soil conditions on the NPL property and surrounding area to produce the highest quality cannabis, hemp and cannabinoid products possible. FSD Jamaica is well-positioned to bring Jamaican branded, world class medical and recreational products to market by 2019”, said Anthony Durkacz, Director of FSD.

As part of the LOI, FSD Jamaica will establish an experimental centre for the development of cannabis and cannabinoid (“CBD”) genetics suitable to cultivate in Jamaica with the intent to create a genetics and seed bank of innovative cannabis and hemp products for the Jamaican market and the Canadian market where permitted.

“NPL was the second company to be granted a cultivation license in Jamaica. It is located in the beautiful mountains of Ulster Springs Trelawny and the property is fed by crystal clear spring water surrounded by many agricultural crops and experienced workers. The combined genetics library of FSD Jamaica and NPL will allow for the breeding of high THC & CBD plants that will be cultivated using medical grade extraction processes. This strategic partnership compliments FSD’s business model of producing the highest quality medical grade product at scale”, continued Mr. Durkacz. Continue Reading

FSD Pharma Breaks All-time Daily Volume Record and Continues to Make History

TORONTO, September 12, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9), is pleased to report that on September 11, 2018 the Company traded an aggregate total of exactly 213,761,823 shares. FSD traded 143,260,988 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”), 1,888,500 on AQC-Lit, 15,369,000 on AQC-Neo, 241,740 on CXC, 5,309,399 on CX2, 6,473,592 on CXD, 22,500 on Lynx, 24,750,500 on Omega and 16,445,604 on MatchNow. This is the largest total quantity of share volume traded by a CSE listed issuer by over 15.7% above the recorded all-time high of 184,718,114 also achieved by FSD on September 10, 2018, as confirmed by the CSE. This record is also  41% over the Company’s previous reporting of achieving an all-time high of 151,183,895 on September 4, 2018.

The company wishes to again thank all its shareholders and stakeholders for their support to date, which has resulted in yet another record-breaking achievement in the Canadian cannabis investment marketplace.
Continue Reading